Prostate cancer is the second leading cause of cancer death in men in the United States. Localized prostate cancer can be cured by androgen ablation, but when the disease escapes the confines of the gland, the prospects for cure decrease drastically and the disease becomes """"""""castrate resistant."""""""" Bone is the primary site of castrate-resistant disease progression, which is associated with a poor prognosis. The fibroblast growth factor (FGF)/FGF receptor (FGFR) complex, a signaling axis involving multiple FGF ligands and receptors, mediates tumor-stromal interactions and is one ofthe most commonly altered signaling pathways during prostate cancer progression. Expression of FGFR1, multiple FGF ligands, and FGFR adaptor, FRS2a has been observed in prostate cancer epithelial cells. Our recent studies have defined a mouse model of prostate cancer highly dependent on FGF signaling, and have implicated FGFQ in the osteoblastic progression of human prostate cancer cells in bone. The results of our preliminary studies support a notion that during bone metastasis, the prostate cancer cells that aberrantly express both FGF and FGFRs creates a new """"""""compartment"""""""" in bone as source and recipient of additional FGF-mediated signaling, thus subverting homeostasis. The implication ofthe FGF axis in prostate cancer progression suggests that FGFR blockade represents a new therapeutic opportunity for men with castrate-resistant prostate cancer. Recently, TKI258, a receptor tyrosine kinase inhibitor (TKl) with strong activity against FGFR1-3 (IC50 <40 nM), has become available and is being used as an experimental new drug for solid tumors. The main goal of this proposed project is to establish the feasibility of using TKI258 to modulate FGF signaling in men with castrate-resistant prostate cancer and to correlate FGF signaling modulation with clinical disease progression. We will assess the effect of TKI258 on human prostate cancer xenografts growing in the prostate and bone of castrated immunodeficient male mice (Aim 1), and also on mouse models of prostate cancer (Aim 2) to identify markers of response to TK1258 therapy directly related to FGF signaling. We will then perform a proof-of-principle clinical study with TKI258 in men with castrate-resistant prostate cancer and bone marrow infiltration (Aim 3). The study will create an annotated tissue resource and will permit validation of FGF signaling responsive markers emerging from Aims 1 and 2. This will be the first clinical study to assess the effect of TKI258 in prostate cancer.

Public Health Relevance

Prostate cancer is the second leading cause of cancer death in men in the United States. In the proposed study we will perform a proof-of-principle clinical study with a receptor tyrosine kinase inhibitor, TK1258 in men with castrate-resistant prostate cancer and bone marrow infiltration. The results of this study will be the foundation for development of further therapies of prostate cancer patients based on targeting the fibroblast growth factor signaling pathway.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140388-04
Application #
8380594
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
4
Fiscal Year
2012
Total Cost
$285,810
Indirect Cost
$99,035
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2017) Enzalutamide and CXCR7 inhibitor Combination Treatment Suppresses Cell Growth and Angiogenic Signaling in Castration-Resistant Prostate Cancer Models. Int J Cancer :
Lin, Song-Chang; Lee, Yu-Chen; Yu, Guoyu et al. (2017) Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Dev Cell 41:467-480.e3
Gao, Jianjun; Ward, John F; Pettaway, Curtis A et al. (2017) VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23:551-555
Yu, Kai-Jie; Li, Jeffrey K; Lee, Yu-Chen et al. (2017) Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone. Oncotarget 8:74987-75006
Tu, Huakang; Gu, Jian; Meng, Qing H et al. (2017) Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett 13:1949-1957
Gökce, Mehmet I; Wang, Xuemei; Frost, Jacqueline et al. (2017) Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men. Cancer 123:583-591
Karanika, Styliani; Karantanos, Theodoros; Li, Likun et al. (2017) Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep 18:1970-1981
Saha, Achinto; Blando, Jorge; Fernandez, Irina et al. (2016) Linneg Sca-1high CD49fhigh prostate cancer cells derived from the Hi-Myc mouse model are tumor-initiating cells with basal-epithelial characteristics and differentiation potential in vitro and in vivo. Oncotarget 7:25194-207
Fong, Eliza L S; Wan, Xinhai; Yang, Jun et al. (2016) A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials 77:164-72
Subudhi, Sumit K; Aparicio, Ana; Gao, Jianjun et al. (2016) Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113:11919-11924

Showing the most recent 10 out of 198 publications